This morning, Luxturna’s maker, Spark Therapeutics, is announcing the cost of this medical miracle: $425,000 per eye, or $850,000 for most patients. In December, the investment bank Jefferies had forecast a $1 million price. It can cost $1 million a year to treat hemophilia in rare cases where patients develop antibodies to the drugs used to prevent clotting. Glybera, a gene therapy for another rare disease, was available in Europe at a $1 million price; it didn’t sell and its maker, UniQure, allowed the product’s marketing clearance to lapse. Express Scripts Miller, while praising the current price, said that he hopes future gene therapies will have lower prices, pointing to the hemophilia treatments Spark is developing.
Source: Forbes January 03, 2018 13:30 UTC